SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine